IDT to acquire AITbiotech


Wednesday, 02 December, 2015

Integrated DNA Technologies (IDT), a provider of synthetic nucleic acids for molecular biology applications, has entered into a definitive agreement to acquire the oligonucleotide synthesis business of AITbiotech — a Singapore-based company that provides a complete suite of genomics services to research, healthcare and biomedical industries in Asia.

The acquisition will see IDT expands its customer base across South-East Asia, making it possible for these additional customers to have access to the company’s broad range of products for genomic applications. AITbiotech will continue operations in its other core business areas.

“With this purchase, we further expand our presence in the region and look forward to welcoming AITbiotech customers to IDT,” said IDT founder and CEO Dr Joseph A Walder. “The entire Singapore scientific research market can now benefit from IDT’s unrivalled manufacturing capabilities, design expertise and fast turnaround times.”

AITbiotech’s founder and CEO, Alex Thian, added, “We share a commitment with IDT to produce consistently high-quality oligos and to provide personal service for customers. Both companies are working diligently to facilitate a smooth transition of the business and we are excited to begin this next chapter in the ever expanding Singapore market.”

Related News

Dr Chris Baldwin is new HaemaLogiX CEO and Managing Director

Having commenced in January, Dr Chris Baldwin is clinical stage Australian biotechnology company...

Vaxxas appoints former Merck Global Vaccines President David Peacock as CEO

To lead the commercialisation of Vaxxas's proprietary high‑density microarray patch (HD‑MAP)...

Optics11 Life appoints Jacquelien ten Dam as CEO

Optics11 Life plans to accelerate its commercial growth in key markets while building strategic...


  • All content Copyright © 2026 Westwick-Farrow Pty Ltd